CYDY 0.15 CytoDyn Inc.
| Range: | 0.11-0.42 | Vol Avg: | 2296168 | Last Div: | 0 | Changes: | 0 |
| Beta: | 0.12 | Cap: | 0.17B | Currency: | USD | Exchange: | PNK |
| Sector: | Healthcare | IPO: | Wed Dec 13 2006 | Empoloyees: | 9 | ||
| CUSIP: | 23283M101 | CIK: | 0001175680 | ISIN: | US23283M1018 | Country: | US |
| CEO: | Dr. Jacob P. Lalezari M.D. | Website: | https://www.cytodyn.com | ||||
CytoDyn Inc. operates as a clinical-stage biotechnology company. The company focuses on developing treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor in the areas of human immunodeficiency virus (HIV), non-alcoholic steatohepatitis (NASH), oncology, and such as coronavirus disease (COVID-19). It is also conducting a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow